Gemvalaz, Valgamez 5/160 mg, 10/160 mg Film-coated tablet
PDF Leaflet Revision Date: 08 November 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of mild to moderate essential hypertension.
Dosage (summary)
One tablet daily; no adjustment for elderly or mild to moderate renal impairment.
Onset of Action / Duration
Onset: 2 hours, Duration: 24 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Lithium
- Potassium-sparing diuretics
- NSAIDs
- CYP3A4 inhibitors
Contraindications
- Hypersensitivity
- Angioedema history
- Severe renal impairment
- Bilateral renal artery stenosis
- Pregnancy
- Lactation
Common side effects
- Dizziness
- Headache
- Fatigue
- Hypotension
- Oedema
Counselling Points
- Take with water
- Monitor blood pressure regularly
- Report signs of angioedema
Serious warnings
- Risk of non-cardiogenic pulmonary oedema
- Dual blockade of RAAS contraindicated
Important Disclaimer
The Gemvalaz, Valgamez 5/160 mg, 10/160 mg Film-coated tablet professional information leaflet below is the property of Ranbaxy Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
